gsk news - Search News

GSK, IDRx

Hosted on MSN · 14h

GSK Nears $1 Billion Deal for Biotech Company IDRx

GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British drugmaker further boost its growing oncology portfolio.

pharmaphorum · 14h

Is GSK prepping a $1bn takeover bid for IDRx?

GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy for a form of rare gastrointestinal stromal tumour (GIST).

Business Insider · 1d

GSK in advanced talks to purchase U.S. biotech IDRx, FT reports

GSK (GSK) is in advanced discussions to purchase privately-owned U.S. biotech IDRx, which is working on a treatment for rare gastrointestinal

Seeking Alpha on MSN · 1d

GSK is said to be nearing $1B deal to acquire U.S. biotech IDRx

British pharma giant GSK (NYSE:GSK) is closing in on a $1B buyout deal to acquire IDRx, a U.S. biotech focused on developing drugs for rare gastrointestinal tumors, The Financial Times reported Wednesday.

GSK, RSV and Pfizer

Hosted on MSN · 1d

GSK and Pfizer's RSV vaccines to carry warnings of neurological disorder risk

GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare neurological disorder, the U.S. Food Drug Administration said on Tuesday.

FiercePharma · 1d

RSV vaccines from Pfizer, GSK take another hit with new FDA warning mandate

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning about the risk of developing Guillain-Barré syndrome (GBS), a rare neurological condition that can cause paralysis.

FDA adds warning to RSV shots from GSK, Pfizer

Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.

6h

GSK falls Thursday, underperforms market

Shares of GSK PLC GSK inched down 0.77% to £13.50 Thursday, on what proved to be an all-around positive trading session for ...

FDA Grants BTD to the ADC GSK’227 in Relapsed/Refractory Osteosarcoma

The FDA has granted BTD to GSK’22, a B7-H3-targeted antibody-drug conjugate, for the treatment of adult patients with ...

ENDPOINTS NEWS6d

GSK’s Nucala bags another China approval, but biggest test yet to come

GSK's Nucala gets China approval for chronic rhinosinusitis with nasal polyps; awaits FDA decision for COPD in May as it ...

1d

GSK rises Wednesday, outperforms market

GSK PLC GSK shares inched up 0.18% to £13.60 Wednesday, on what proved to be an all-around favorable trading session for the ...

Hosted on MSN2d

GSK's ADC Drug Gets FDA's Breakthrough Tag for Rare Bone Cancer

GSK plc GSK announced that the FDA has granted a Breakthrough Therapy Designation to its investigational B7-H3-targeted ...

2d

Bernstein Remains a Buy on GlaxoSmithKline (GSK)

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results